CN115537356A - Compound probiotic with effect of preventing or relieving blood pressure increase and preparation method and application thereof - Google Patents
Compound probiotic with effect of preventing or relieving blood pressure increase and preparation method and application thereof Download PDFInfo
- Publication number
- CN115537356A CN115537356A CN202211241806.0A CN202211241806A CN115537356A CN 115537356 A CN115537356 A CN 115537356A CN 202211241806 A CN202211241806 A CN 202211241806A CN 115537356 A CN115537356 A CN 115537356A
- Authority
- CN
- China
- Prior art keywords
- preparation
- blood pressure
- probiotic
- preventing
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 69
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 69
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 230000036772 blood pressure Effects 0.000 title claims abstract description 36
- 230000000694 effects Effects 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 title description 4
- 239000002131 composite material Substances 0.000 claims abstract description 34
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 20
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 20
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 20
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 18
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 18
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 18
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims abstract description 18
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 18
- 229940054346 lactobacillus helveticus Drugs 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 229920002472 Starch Polymers 0.000 claims description 13
- 229940032147 starch Drugs 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 12
- 150000005846 sugar alcohols Chemical class 0.000 claims description 11
- 229920001202 Inulin Polymers 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 9
- 229940029339 inulin Drugs 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 235000013406 prebiotics Nutrition 0.000 claims description 5
- 239000003223 protective agent Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 235000020183 skimmed milk Nutrition 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 229920000107 Acetylated distarch adipate Polymers 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 102000011632 Caseins Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 229920003012 Hydroxypropyl distarch phosphate Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- 239000004383 Steviol glycoside Substances 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000001245 distarch phosphate Substances 0.000 claims description 2
- 235000013804 distarch phosphate Nutrition 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000001310 hydroxy propyl distarch phosphate Substances 0.000 claims description 2
- 235000013825 hydroxy propyl distarch phosphate Nutrition 0.000 claims description 2
- DVROLKBAWTYHHD-UHFFFAOYSA-N hydroxy propyl distarch phosphate Chemical compound OC1C(O)C(OC)OC(CO)C1OC(O)CCOC1C(OC2C(C(O)C(OC3C(C(OP(O)(=O)OC4C(C(O)C(OC)OC4CO)O)C(C)OC3CO)O)OC2COC2C(C(O)C(OC)C(CO)O2)O)O)OC(CO)C(OC)C1O DVROLKBAWTYHHD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229940080237 sodium caseinate Drugs 0.000 claims description 2
- 229940080313 sodium starch Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 235000019411 steviol glycoside Nutrition 0.000 claims description 2
- 229930182488 steviol glycoside Natural products 0.000 claims description 2
- 150000008144 steviol glycosides Chemical class 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 239000000047 product Substances 0.000 description 13
- 238000004321 preservation Methods 0.000 description 11
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 10
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 10
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100024547 Tensin-1 Human genes 0.000 description 4
- 108010088950 Tensins Proteins 0.000 description 4
- 239000003833 bile salt Substances 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/245—Lactobacillus casei
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a composite probiotic agent with the effect of preventing or relieving blood pressure rise and a preparation method and application thereof, wherein probiotics in the composite probiotic agent comprise a Lactobacillus plantarum Lp05 strain, a Lactobacillus casei LC89 strain and a Lactobacillus helveticus LH76 strain. The three strains are creatively compounded to obtain the composite probiotic preparation, all components are mutually matched and synergized synergistically, and compared with a single strain, the composite probiotic preparation has a more remarkable effect of relieving the increase of blood pressure. The composite probiotic can be further applied to the preparation of food, health-care products or medicines.
Description
Technical Field
The invention belongs to the technical field of probiotics, and relates to a compound probiotic with the efficacy of preventing or relieving blood pressure rise, and a preparation method and application thereof.
Background
Hypertension is the most common cardiovascular disease discovered so far, and is also the main pathogenesis of diseases such as sudden brain death, coronary heart disease and kidney failure, so the prevention and treatment of hypertension can reduce the risk of cardiovascular system diseases. At present, people pay more attention to research, prevention and treatment of hypertension, and the multifunctional food research in the aspect of reducing blood pressure plays an important role. Hypertension has been shown to be caused by a variety of causes, including neurological, genetic, psychiatric, endocrine, and Angiotensin Converting Enzyme (ACE), among others.
The mechanism of lowering blood pressure in the human body is generally regulated and controlled by a renin-angiotensin system and a kinin-regenerating enzyme system, which are antagonistic systems. In human body, after the renin flows into the blood plasma, angiotensinogen in the blood plasma is hydrolyzed to obtain capillary tensin I (AT 1); due to the function of angiotensin converting enzyme ACE, capillary tensin I is converted into capillary tensin II (Ang II), so that capillary tensin II can not only improve the contractile ability of the heart, but also can cause the high pressure increase caused by the contraction of vascular smooth muscle. At the same time, ACE also regulates the kallikrein system, leading to the conversion of bradykinin, which has a bradykinin function, into inactive sustained release peptides. ACE acts synergistically on these two systems, causing the rise of high pressure in the human body. To achieve a decrease in blood pressure, inhibition of ACE activity is necessary.
ACE can also directly activate adrenal cortex to release aldosterone, and the main action mechanism of aldosterone is that the excretion of salt and water by kidney is reduced, so that the extracellular fluid volume and the plasma volume of human body are increased, the venous return current is increased, and hypertension is indirectly induced. The protease produced by the lactobacillus plantarum cuts off partial active fragments and releases the active fragments at the same time, the partial active fragments are fused with the active center of ACE, the activity of the ACE is competitively controlled, angiotensin I cannot be converted into angiotensin II, and the purpose of reducing blood pressure is achieved.
The primary antihypertensive drugs proposed today are five major classes of beta-blockers, diuretics, angiotensin converting enzyme inhibitory drugs (ACEIs), calcium channel blockers, angiotensin ii dual receptor binding inhibitors, and the like. Each drug has its own characteristics and also has certain side effects.
The ACEI has certain curative effect on hypertension patients in all periods, does not cause the increase of heart rate or interfere the regulation effect of a parasympathetic nervous system on vascular smooth muscle, but has the main adverse reaction that proteinuria, rash, leukopenia and the like are easy to generate through synthesized ACEI. Treatment with antihypertensive drugs is responsible for an increased incidence of coronary heart disease; alterations in metabolism, particularly potentially adverse effects on sugar, fat and uric acid metabolism, are affected during drug therapy; the probability of cerebral blood reduction caused by blood pressure reduction caused by drug therapy is increased, and visual disturbance, cerebral ischemia, cerebral arterial thrombosis and the like can be caused at the same time. Therefore, the non-drug treatment of hypertension is gaining more and more attention.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a composite probiotic with the efficacy of preventing or relieving blood pressure rise and a preparation method and application thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the invention provides a composite probiotic preparation with the efficacy of preventing or relieving blood pressure increase, wherein probiotics in the composite probiotic preparation comprise Lactobacillus plantarum Lp05 strain, lactobacillus casei LC89 strain and Lactobacillus helveticus LH76 strain.
The Lactobacillus plantarum Lp05 strain, the Lactobacillus casei LC89 strain and the Lactobacillus helveticus LH76 strain are creatively compounded to obtain the composite probiotic agent, all components are mutually matched for synergy, and compared with a single strain, the composite probiotic agent has a more remarkable effect of relieving the increase of blood pressure.
Preferably, the viable count ratio of the Lactobacillus plantarum Lp05 strain, the Lactobacillus casei LC89 strain and the Lactobacillus helveticus LH76 strain is (10-20): (5-10): (15-30).
The specific point value in the (10-20) can be selected from 10, 12, 14, 15, 16, 17, 18, 20 and the like.
The specific point value in (5-10) can be selected from 5, 6, 7, 8, 9, 10 and the like.
The specific point value in (15-30) can be selected from 15, 17, 18, 20, 22, 25, 28, 30 and the like.
Other specific values within the above ranges can be selected, and are not described in detail herein.
Preferably, the complex probiotic also comprises a protective agent.
Preferably, the protectant comprises skim milk and/or skim milk powder.
Preferably, the complex probiotic further comprises a carrier.
Preferably, the carrier comprises any one of microcrystalline cellulose, inulin, magnesium stearate, a sugar alcohol or starch, or a combination of at least two thereof.
Preferably, the carrier is a combination of microcrystalline cellulose, a sugar alcohol, inulin and starch.
The combination of microcrystalline cellulose, sugar alcohol, inulin and starch is more preferable as the complex probiotic agent is more stable in this combination mode, and can maintain the shape and mouthfeel of the product for a long time.
Preferably, the sugar alcohol is selected from any one of xylitol, maltitol, erythritol, sorbitol, isomalt or lactitol or a combination of at least two thereof.
Preferably, the starch is selected from any one of or a combination of at least two of acetate starch, sodium starch octenyl succinate, hydroxypropyl distarch phosphate, phosphate distarch, acid-treated starch, oxidized hydroxypropyl starch, acetylated distarch phosphate or acetylated distarch adipate.
The dosage form of the composite probiotic preparation can be freeze-dried powder, tablets, capsules, solutions, emulsions and the like.
In a second aspect, the present invention provides a method for preparing a complex probiotic with efficacy of preventing or alleviating blood pressure increase according to the first aspect, the method comprising:
(1) Mixing Lactobacillus plantarum Lp05, lactobacillus casei LC89 and Lactobacillus helveticus LH76 with a protective agent according to a ratio to obtain an emulsion;
(2) Mixing the emulsion obtained in the step (1) with a carrier, and carrying out micro-embedding treatment to obtain an embedding mixture;
(3) And (3) carrying out electrostatic spray drying on the embedding mixture obtained in the step (2) to obtain the composite probiotic preparation with the effect of preventing or relieving the blood pressure rise.
In a third aspect, the invention provides the use of the complex probiotic with the effect of preventing or relieving blood pressure increase in the preparation of food, health products or medicines.
In a fourth aspect, the invention provides a probiotic beverage, which comprises the following preparation raw materials in percentage by mass: 0.01-10% of composite probiotic agent, 0.01-5% of prebiotics, 0.1-1% of stabilizing agent, 0.01-0.05% of sweetening agent and water.
The mass percentage of the composite probiotic can be selected from 0.01%, 0.1%, 1%, 2%, 3%, 5%, 7%, 8%, 10% and the like.
The prebiotics can be selected from 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 3.5%, 4%, 5% and the like in percentage by mass.
The mass percentage of the stabilizer can be selected from 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 1% and the like.
The mass percentage of the sweetener can be selected from 0.01%, 0.02%, 0.03%, 0.04%, 0.05% and the like.
Other specific point values within the above numerical ranges can be selected, and are not described in detail herein.
Preferably, the prebiotics are selected from any one or a combination of at least two of stachyose, fructo-oligosaccharide, isomalto-oligosaccharide or galacto-oligosaccharide.
Preferably, the sweetener is selected from any one of acesulfame k, aspartame, sucralose or steviol glycosides or a combination of at least two thereof.
Preferably, the stabilizer is selected from any one or a combination of at least two of sodium carboxymethylcellulose, pectin, soybean polysaccharide, agar or sodium caseinate; a combination of pectin and soy polysaccharide is preferred.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively compounds three strains of Lactobacillus plantarum Lp05 strain, lactobacillus casei LC89 strain and Lactobacillus helveticus LH76 strain to obtain the composite probiotic preparation, and the components are mutually matched for synergism.
Detailed Description
To further illustrate the technical means and effects of the present invention, the following further describes the technical solution of the present invention with reference to the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
(1) The Lactobacillus plantarum Lp05 related to the following is Lactobacillus plantarum Lp05 strain, the preservation unit is China general microbiological culture Collection center (CGMCC) No.23547, the preservation date is 2021 year, 10 month and 09 day, and the preservation address is No. 3 of Xilu No.1 Beicheng sunward area, beijing.
(2) The Lactobacillus helveticus LH76 is Lactobacillus helveticus LH76 strain, the preservation unit is China general microbiological culture Collection center, the preservation number is CGMCC No.18796, the preservation date is 11, 4 and 2019, and the preservation address is No. 3 of Xilu No.1 of the morning district of Beijing.
(3) The Lactobacillus casei LC89 is Lactobacillus casei LC89 strain, the preservation unit is China general microbiological culture Collection center, the preservation number is CGMCC No.15409, the preservation date is 03-05 days in 2018, and the preservation address is Beijing City Zhongyang district Xilu No.1 Beijing No. 3.
The following related MRS solid culture media: weighing 10g of peptone, 10g of beef extract, 20g of glucose, 10g of lactose, 5g of yeast extract, 2g of diammonium hydrogen citrate and K 2 PO 4 ·3H 2 O 2g、MgSO 4 ·7H 2 O 0.6g、MnSO 4 Dissolving 0.01g of agar, 20g of agar and 1g of L-cysteine by using deionized water, adding 1mL of Tween 80, diluting to a constant volume of 1L, sterilizing, cooling, and pouring into a sterilized culture dish for later use.
The following related MRS liquid culture media: weighing 10g of peptone, 10g of beef extract, 20g of glucose, 10g of lactose, 5g of yeast extract, 2g of diammonium hydrogen citrate and K 2 PO 4 ·3H 2 O 2g、MgSO 4 ·7H 2 O 0.6g、MnSO 4 0.01g and 1g of L-cysteine, dissolving with deionized water, adding 1mL of Tween 80, diluting to 1L, sterilizing, cooling, and pouring into a sterilized culture dish for later use.
The following bacterial suspensions of lactobacillus plantarum Lp05, lactobacillus helveticus LH76 and lactobacillus casei LC89 are involved: inoculating the bacteria in an MRS liquid culture medium, culturing at 38 ℃ for 18h for activation, and continuously activating for 2 times to obtain an activated solution; inoculating the activated liquid into an MRS liquid culture medium according to the inoculation amount of 2% (v/v), and culturing at 38 ℃ for 18h to obtain a bacterial liquid; centrifuging the bacterial liquid at 8000g for 10min, and filtering the supernatant with 0.22 μm sterile filter membrane to obtain supernatant; and (5) resuspending the thallus by using PBS.
The sources of the components in the following examples are as follows:
example 1
This example demonstrates the gastric acid resistance of three bacteria, with the following steps:
(1) Preparing artificial gastric juice:
the artificial gastric juice contains 0.20% of NaCl and 0.30% of pepsin by mass fraction, the pH is adjusted to 3.0 by using HCl, and the artificial gastric juice is filtered and sterilized for later use.
(2) And (3) testing gastric acid resistance:
taking 1.0mL of Lactobacillus plantarum Lp05, lactobacillus helveticus LH76 and Lactobacillus casei LC89 bacterial suspension (the concentration is 1 × 10) 9 CFU/mL, adopting the method in national standard GB4789.35-2016 food safety national standard food microbiology detection of lactic acid bacteria detection) to measure the concentration of bacterial liquid), respectively mixing with 9.0mL of artificial gastric juice with pH of 3.0, carrying out anaerobic static culture at 37 ℃, respectively sampling after 0h of starting and 3h of treatment, determining the viable count by a pouring culture method and calculating the survival rate, wherein the formula is as follows:
survival (%) = N1/N0 × 100%,
wherein, N1: viable count after 3h of artificial gastric juice treatment; n0: viable count of 0 h. The test results are shown in Table 1.
TABLE 1
As can be seen from the data in Table 1: the probiotics provided by the invention have good gastric acid resistance, and the good acid resistance creates conditions for preparing products for preventing or relieving hypertension.
Example 2
This example demonstrates the bile salt resistance of three bacteria, as follows:
adjusting the content of the bacterial liquid to 10 8 centrifuging at 3000r/min for 10min at cfu/ml, removing supernatant, adding sterilized MRS liquid culture medium containing 0.3% bile salt into the centrifuged thallus, shaking uniformly, placing into a 37 ℃ constant temperature incubator, continuously taking samples within 0h and 3h, diluting with sterilized PBS, coating on an MRS plate, incubating at 37 ℃ for 36h, and counting. The formula is as follows:
survival (%) = N1/N0 × 100%,
wherein, N1: the number of viable bacteria after 3 hours of treatment; n0: viable count of 0 h. The test results are shown in Table 2.
TABLE 2
Bacterial strains | Viable count N0 (0 h) | Viable count N1 (3 h) | Survival rate (%) |
Lactobacillus plantarum Lp05 | (7.98±0.06)×10 8 | (7.04±0.10)×10 8 | 90.3% |
Lactobacillus helveticus LH76 | (7.25±0.12)×10 8 | (6.56±0.08)×10 8 | 90.5% |
Lactobacillus casei LC89 | (7.16±0.09)×10 8 | (6.51±0.13)×10 8 | 91.0% |
From the data in table 2 it can be seen that: the probiotics provided by the invention have good bile salt resistance, and the good bile salt resistance creates conditions for preparing products for preventing or relieving hypertension.
Example 3
The embodiment provides a composite probiotic with the efficacy of preventing or relieving blood pressure increase, and the preparation method comprises the following steps:
(1) Mixing 40 parts of bacterial powder (the viable count of Lactobacillus plantarum Lp05, lactobacillus casei LC89 and Lactobacillus helveticus LH76 is 15);
(2) Mixing the emulsion obtained in the step (1) with a carrier (5 parts of microcrystalline cellulose, 5 parts of sugar alcohol, 10 parts of inulin and 10 parts of starch), and carrying out micro-embedding treatment to obtain an embedding mixture;
(3) And (3) carrying out electrostatic spray drying on the embedding mixture obtained in the step (2) to obtain the composite probiotic preparation with the effect of preventing or relieving the blood pressure rise.
Example 4
The embodiment provides a composite probiotic with the efficacy of preventing or relieving blood pressure increase, and the preparation method is different from the embodiment 3 only in that 40 parts of Lactobacillus plantarum Lp05 and Lactobacillus casei LC89 are prepared from Lactobacillus plantarum with the viable count of 15. The other steps were kept unchanged.
Example 5
The embodiment provides a composite probiotic preparation with the efficacy of preventing or relieving blood pressure increase, and the preparation method is different from the embodiment 3 only in that 40 parts of Lactobacillus plantarum Lp05 and Lactobacillus helveticus LH76 with the viable count of bacterial powder being 15. The other steps were kept unchanged.
Example 6
The embodiment provides a composite probiotic preparation with the efficacy of preventing or relieving blood pressure increase, and the preparation method is different from the embodiment 3 only in that 40 parts of Lactobacillus casei LC89 and Lactobacillus helveticus LH76 with the viable count of 5. The other steps were kept unchanged.
Example 7
This example provides a complex probiotic with efficacy of preventing or alleviating blood pressure elevation, and the preparation method differs from example 3 only in that the carriers in step (2) are 10 parts of sugar alcohol, 10 parts of inulin and 10 parts of starch. The other steps were kept unchanged.
Example 8
The present example provides a complex probiotic with efficacy of preventing or alleviating blood pressure increase, and the preparation method is different from example 3 only in that the carriers in step (2) are 10 parts of microcrystalline cellulose, 10 parts of inulin and 10 parts of starch. The other steps were kept unchanged.
Example 9
The present example provides a composite probiotic preparation with efficacy of preventing or alleviating blood pressure increase, and the preparation method is different from example 3 only in that the carrier in step (2) is 5 parts of microcrystalline cellulose, 5 parts of sugar alcohol, and 20 parts of starch. The other steps were kept unchanged.
Example 10
The present example provides a composite probiotic preparation with efficacy of preventing or alleviating blood pressure increase, and the preparation method is different from example 3 only in that the carriers in step (2) are 5 parts of microcrystalline cellulose, 5 parts of sugar alcohol, and 20 parts of inulin. The other steps were kept unchanged.
Test example 1
And (3) measuring the blood pressure reducing effect of the composite probiotic:
(1) Experimental animals: male primary Severe Hypertension Rats (SHR), about eight weeks old, with an average weight of 170-210 g, supplied by the laboratory animal management center in shanghai city, department of china, animal certification number: hu Dong He Zheng character 152. Male SD rats, 8 weeks old, weighing 170-210 g, were supplied by the laboratory mammal management center, shanghai city, chinese academy of sciences, and the animals met the qualifications number: hu Dong He Zheng character 152. The indoor illumination of the animals is 12h illumination, indoor ventilation and air conditioning equipment is normal, the room temperature is controlled to be 22 +/-3 ℃, and the relative humidity is about 50-70%.
(2) The experimental animal is adapted to the environment for 7 days, adaptive manometry is carried out, continuous gavage is started after the blood pressure is stable, and the experimental gavage time is 9 a.m. every day. 40 SHR rats were randomly divided into 5 groups: model control, example 3, example 4, example 5, example 6; 8 SD rats were used as SD control group. The normal saline for gastric lavage of the control group, the composite probiotic prepared in each example for gastric lavage of the example group are 10mg/kg.
(3) The rat carries out pressure test one week before administration, and tests are carried out after the pressure reduction is stable, wherein the pressure reduction before administration is firstly measured, then the rat is subjected to intragastric administration, the intragastric administration is carried out once a day, the intragastric administration is continuously carried out for 4 weeks, the high pressure of the tail artery of the SHR is measured by using a BP-98A intelligent noninvasive sphygmomanometer, the steps are repeated for three times, an average value is obtained, and the measured value is displayed in the form of the average value. As shown in table 3.
TABLE 3
From the data results of table 3, it can be seen that: the composite probiotic preparation has the obvious effect of relieving the blood pressure rise, and the lactobacillus plantarum Lp05 strain, the lactobacillus casei LC89 strain and the lactobacillus helveticus LH76 strain in the composite probiotic preparation have the synergistic effect on the effect.
Application example 1
The application example provides a probiotic beverage, and the preparation raw materials of the probiotic beverage comprise the following components in percentage by mass: 5% of the composite probiotic prepared in the embodiment 3, 5% of fructo-oligosaccharide, 0.5% of pectin, 0.5% of soybean polysaccharide, 0.04% of sucralose and the balance of water.
Application examples 2 to 8
The application example provides seven probiotic beverages, the preparation raw materials of the probiotic beverage are different from those of the application example 1 only in that the composite probiotic prepared in the example 3 is replaced by the same amount of the composite probiotic prepared in the examples 4 to 10, and other raw materials and content are kept unchanged.
Test example 2
Testing of stability of probiotic beverages:
the probiotic beverages of application examples 1-8 were stored refrigerated at 4 ℃ for 21 days and the state of the tissue was visually observed. The products of each group are graded, wherein the layering phenomenon is obvious when the product is graded, the layering phenomenon is not obvious when the product is graded, and the product is very uniform when the product is not layered when the product is graded. The results are shown in Table 4.
TABLE 4
Sample (I) | Score the points |
Application example 1 | 3 |
Application example 2 | 3 |
Application example 3 | 3 |
Application example 4 | 3 |
Application example 5 | 2 |
Application example 6 | 1 |
Application example 7 | 1 |
Application example 8 | 2 |
From the results of table 4, it can be seen that: the beverage product prepared by using the composite probiotic disclosed by the invention has good stability, wherein the stability of the beverage product is obviously influenced by the composition mode of the carrier material in the composite probiotic.
The applicant states that the present invention is described by the above examples, but the present invention is not limited to the above examples, i.e. it does not mean that the present invention must be implemented by the above examples. It should be understood by those skilled in the art that any modifications of the present invention, equivalent substitutions of the raw materials of the product of the present invention, and the addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that, in the above embodiments, the various features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, the present invention does not separately describe various possible combinations.
Claims (10)
1. The composite probiotic preparation with the effect of preventing or relieving the blood pressure rise is characterized in that probiotics in the composite probiotic preparation comprise Lactobacillus plantarum Lp05 strain, lactobacillus casei LC89 strain and Lactobacillus helveticus LH76 strain.
2. The complex probiotic preparation with the effect of preventing or relieving blood pressure increase according to claim 1, wherein the viable count ratio of Lactobacillus plantarum Lp05 strain, lactobacillus casei LC89 strain and Lactobacillus helveticus LH76 strain is (10-20): (5-10): (15-30).
3. The complex probiotic with the efficacy of preventing or alleviating blood pressure elevation according to claim 1 or 2, characterized in that the complex probiotic further comprises a protective agent;
preferably, the protective agent comprises skim milk and/or skim milk powder.
4. The complex probiotic with the efficacy of preventing or alleviating blood pressure elevation according to any one of claims 1 to 3, characterized in that the complex probiotic further comprises a carrier;
preferably, the carrier comprises any one or a combination of at least two of microcrystalline cellulose, inulin, magnesium stearate, a sugar alcohol or starch;
preferably, the carrier is a combination of microcrystalline cellulose, a sugar alcohol, inulin and starch.
5. The complex probiotic preparation with the efficacy of preventing or alleviating blood pressure increase according to claim 4, characterized in that the sugar alcohol is selected from any one or a combination of at least two of xylitol, maltitol, erythritol, sorbitol, isomalt or lactitol;
preferably, the starch is selected from any one of or a combination of at least two of acetate starch, sodium starch octenyl succinate, hydroxypropyl distarch phosphate, phosphate distarch, acid-treated starch, oxidized hydroxypropyl starch, acetylated distarch phosphate or acetylated distarch adipate.
6. The preparation method of the complex probiotic with the efficacy of preventing or alleviating blood pressure increase according to any one of claims 1 to 5, wherein the preparation method comprises the following steps:
(1) Mixing Lactobacillus plantarum Lp05, lactobacillus casei LC89 and Lactobacillus helveticus LH76 with a protective agent according to a ratio to obtain an emulsion;
(2) Mixing the emulsion obtained in the step (1) with a carrier, and carrying out micro-embedding treatment to obtain an embedding mixture;
(3) And (3) carrying out electrostatic spray drying on the embedding mixture obtained in the step (2) to obtain the composite probiotic preparation with the effect of preventing or relieving the blood pressure rise.
7. Use of the complex probiotic preparation with the effect of preventing or alleviating blood pressure increase according to any one of claims 1 to 5 in the preparation of food, health products or medicines.
8. The probiotic beverage is characterized by comprising the following preparation raw materials in percentage by mass: the complex probiotic preparation of any one of claims 1 to 5, 0.01 to 10 percent of prebiotics, 0.01 to 5 percent of stabilizer, 0.1 to 1 percent of sweetening agent, 0.01 to 0.05 percent of water.
9. The probiotic beverage according to claim 8, characterized in that the prebiotic is selected from any one of stachyose, fructo-oligosaccharide, isomalto-oligosaccharide or galacto-oligosaccharide or a combination of at least two thereof;
preferably, the sweetener is selected from any one of acesulfame k, aspartame, sucralose or steviol glycosides or a combination of at least two thereof.
10. The probiotic beverage according to claim 8, characterized in that the stabilizer is selected from any one of or a combination of at least two of sodium carboxymethylcellulose, pectin, soy polysaccharide, agar or sodium caseinate; a combination of pectin and soy polysaccharide is preferred.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211241806.0A CN115537356B (en) | 2022-10-11 | 2022-10-11 | Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211241806.0A CN115537356B (en) | 2022-10-11 | 2022-10-11 | Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115537356A true CN115537356A (en) | 2022-12-30 |
CN115537356B CN115537356B (en) | 2024-02-13 |
Family
ID=84733433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211241806.0A Active CN115537356B (en) | 2022-10-11 | 2022-10-11 | Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115537356B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116515684A (en) * | 2023-03-29 | 2023-08-01 | 微康益生菌(苏州)股份有限公司 | Probiotic agent for improving hyperphosphatemia and application thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008050269A (en) * | 2006-08-22 | 2008-03-06 | Gekkeikan Sake Co Ltd | Oral ingestion material |
CN110179120A (en) * | 2018-02-22 | 2019-08-30 | 杨涵 | A kind of compound diet of probiotics pectase corn peptide improving immunity lower hyperlipidemia, hypertension, hyperglycemia |
CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
CN113755357A (en) * | 2020-06-04 | 2021-12-07 | 内蒙古伊利实业集团股份有限公司 | Lactobacillus preparation and application thereof |
CN113980878A (en) * | 2021-12-29 | 2022-01-28 | 微康益生菌(苏州)股份有限公司 | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof |
CN114651984A (en) * | 2022-03-30 | 2022-06-24 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus casei LC89 and microbial preparation containing same in preparation of product for relieving functional constipation |
CN114854643A (en) * | 2022-06-02 | 2022-08-05 | 微康益生菌(苏州)股份有限公司 | Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof |
-
2022
- 2022-10-11 CN CN202211241806.0A patent/CN115537356B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008050269A (en) * | 2006-08-22 | 2008-03-06 | Gekkeikan Sake Co Ltd | Oral ingestion material |
CN110179120A (en) * | 2018-02-22 | 2019-08-30 | 杨涵 | A kind of compound diet of probiotics pectase corn peptide improving immunity lower hyperlipidemia, hypertension, hyperglycemia |
CN113755357A (en) * | 2020-06-04 | 2021-12-07 | 内蒙古伊利实业集团股份有限公司 | Lactobacillus preparation and application thereof |
CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
CN113980878A (en) * | 2021-12-29 | 2022-01-28 | 微康益生菌(苏州)股份有限公司 | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof |
CN114651984A (en) * | 2022-03-30 | 2022-06-24 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus casei LC89 and microbial preparation containing same in preparation of product for relieving functional constipation |
CN114854643A (en) * | 2022-06-02 | 2022-08-05 | 微康益生菌(苏州)股份有限公司 | Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116515684A (en) * | 2023-03-29 | 2023-08-01 | 微康益生菌(苏州)股份有限公司 | Probiotic agent for improving hyperphosphatemia and application thereof |
CN116515684B (en) * | 2023-03-29 | 2024-03-01 | 微康益生菌(苏州)股份有限公司 | Probiotic agent for improving hyperphosphatemia and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN115537356B (en) | 2024-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11268064B2 (en) | Lactobacillus rhamnosus RHT-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases | |
EP3501527B1 (en) | Composition for preventing or treating mental disorder, containinglactobacillus | |
TW202038979A (en) | Compositions comprising bacterial strains | |
JP7442195B2 (en) | Lactobacillus crispatus KBL693 strain and its use | |
KR20140000620A (en) | Probiotic strains for use in improving the enteric nervous system | |
JP5046684B2 (en) | Intestinal barrier function recovery agent and intestinal barrier permeability enhancement inhibitor | |
CN102149383A (en) | Pharmaceutical agent, food or beverage having inhibitory activity on serotonin transporter | |
CN115537356A (en) | Compound probiotic with effect of preventing or relieving blood pressure increase and preparation method and application thereof | |
KR102526564B1 (en) | Composition for preventing or treating inflammatory disease comprising Lactibacillus sakei CVL-001 strain | |
CN102429034A (en) | Composite colostrum | |
JP2021505211A (en) | Probiotics for suppressing and preventing the progression of kidney disease and compositions for suppressing and preventing the progression of kidney disease containing the same. | |
JP6261688B2 (en) | QOL improvement or persistence agent | |
KR102568093B1 (en) | Composition for preventing or treating allergic diseases comprising Bifidobacterium longum as an active ingredient | |
KR20150000110A (en) | A composition for the treatment or prevention of asthma comprising alginate | |
JP5422200B2 (en) | Liver dysfunction improving agent | |
JP6280398B2 (en) | GLP-1 secretion promoter | |
US20130224252A1 (en) | Intestine immunomodulator | |
JPH09124498A (en) | Antiallergic agent comprising ellagitannin of god type as active ingredient and food and medicine mixed with the same | |
EP1642963B1 (en) | Lactobacillus casei lc2w strain and its use in antihypertensive aspect | |
WO2022134658A1 (en) | Bifidobacterium breve strain capable of preventing and alleviating psoriasis, and application thereof | |
US20240108665A1 (en) | Composition for preventing, alleviating or treating sleep disorders, containing, as active ingredient, gut microbiota or extracellular vesicles derived therefrom | |
US20240156886A1 (en) | Gos pre-conditioning lactobacillus strains and gos in final formulation | |
RU2798872C2 (en) | Strain lactobacillus gasseri kbl697 and its use | |
US20240245087A1 (en) | Fermented Camel Milk with Propolis-Engineered Probiotic for Treating Adverse Bowel Disorders | |
CN115521883A (en) | Probiotics with functions of relieving pressure and improving sleep |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |